Skip to main content
. 2015 Feb 28;6(10):8388–8396. doi: 10.18632/oncotarget.3460

Table 3. Univariate analyses of overall survival.

N 2-year OS (95%CI) p
All patients 67 24% (15-37)
Cytogenetics
 Intermediate 35 27% (15-49) 0.351
 Unfavorable 32 20% (10-41)
Intermediate risk
ASXL1-wt 21 37% (20-70) 0.030
ASXL1-mut 14 14% (4-52)
Unfavorable risk
TP53-wt 21 26% (12-56) 0.040
TP53-mut 11 9% (1-59)
Genotype
No mutation 41 29% (17-49) 0.005
ASXL1 or TP53 mut 26 15% (7-38)